> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hiers Enterprises Hit With 483 After Inspection
- URL: https://www.fdaweb.com/hiers-enterprises-hit-with-483-after-inspection/
- Published: 2022-04-15T12:00:00.000Z
- Updated: 2026-09-14T17:40:56.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151611

FDA has issued Hiers Enterprises (dba Northwest Compounding Pharmacy) a Form FDA-483 after inspecting the firm in 11/2021\. The inspection cited the firm for producing hazardous drugs without providing adequate containment and cleaning of utensils to prevent cross-contamination. FDA also said the firm compounded drug products containing beta-lactam antibiotics amoxicillin and cephalexin without adequate containment, segregation, or cleaning procedures to prevent cross-contamination with other drug products. And FDA cited personnel that did not change gloves frequently enough to prevent contamination. To view the Form-483, click [here](https://www.fda.gov/media/156961/download?ref=fdaweb.com).